Multicenter Prospective Randomized Trial Comparing Standard Esophagectomy With Chemoradiotherapy for Treatment of Squamous Esophageal Cancer: Early Results From the Chinese University Research Group for Esophageal Cancer (CURE)

Chiu, Philip Wai Yan; Chan, Angus C.W.; Leung, Sing-fai; Leong, Hio Teng; Kwong, Karen L.; Li, Micheal K.W.; Au-Yeung, Alex; Chung, S. C. S.; Ng, Enders K.

doi:10.1016/j.gassur.2005.05.005

Cited by 145 publications

(121 citation statements)

References 39 publications

Supporting

Mentioning

116

Contrasting

Unclassified

Order By: Relevance

“…Epidemiological studies indicate that ESCC is the fifth most common cause of cancer-related mortality in men (1). Despite significant improvements in diagnosis and treatment including surgery, chemotherapy and radiotherapy, patient prognosis remains poor, with a 5-year survival rate of 15-34% (2)(3)(4). Systemic chemotherapy with cisplatin and 5-fluorouracil (5-FU) is the most commonly used treatment regimen for advanced ESCC.…”

Section: Introductionmentioning

confidence: 99%

Cetuximab inhibits cisplatin-induced activation of EGFR signaling in esophageal squamous cell carcinoma

et al. 2014

View full text Add to dashboard Cite

Abstract.A malignant esophageal cancer, squamous cell carcinoma is one of the most prevalent cancers. Despite the use of present surgical techniques combined with various treatment modalities, the overall 5-year survival rate remains at 15-34%. Epidermal growth factor receptor (EGFR) is the most well studied receptor in various cancers and EGFR overexpression is detected in 40% of esophageal squamous cell carcinomas (ESCCs) and ESCC cell lines. To examine the EGFR antibody combination effect, we used treatment with cisplatin and cetuximab in ESCC cell lines, TE-4 and TE-8. Combination of cetuximab and cisplatin resulted in a growth inhibition only in the EGFR overexpressed TE-8 cell line. Furthermore, we confirmed that cisplatin-induced EGFR activation was inhibited by cetuximab in TE-8 but not in TE-4 cells. Our data suggest that cetuximab combined with cisplatin exerts antitumorigenic effects in vitro and in vivo via suppression of EGF signaling, which can be applied toward targeted ESCC treatments.

show abstract

Section: Introductionmentioning

confidence: 99%

Cetuximab inhibits cisplatin-induced activation of EGFR signaling in esophageal squamous cell carcinoma

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Reported studies showed no significant differences in 2-year survival rates, of patients treated with definitive CRT compared to those treated with surgery alone (Chiu et al, 2005), and compared to patients treated with CRT and surgery (Stahl et al, 2005;Bedenne et al, 2007) and suggested that adding surgery conferred no additional benefit.…”

Section: Discussionmentioning

confidence: 99%

Chemoradiation Compared to Surgery Alone in Patients With Non- Metastatic Esophageal Carcinoma

Elsayed¹,

Maximos²

2014

CCO

View full text Add to dashboard Cite

Purpose: To assess overall survival (OS) of esophageal cancer patients treated either by esophagectomy or chemoradiation (CRT). Methods:The medical records of patients with non metastatic esophageal cancer, treated with esophagectomy and those treated with concurrent CRT were analyzed. For all patients, files were reviewed for age, sex, tumor site and type, grade, disease stage and survival. The Log-rank test was used to examine differences in OS rates. Results:The medical records of 90 patients were analyzed. After a median follow up of 20 months, 2-year OS rate for the whole group was 46%. There was significant differences in 2-year OS in favor of patients treated by concurrent CRT (55.4%) compared to those treated by surgery (31%) (p=0.016, HR:1.96, 95% CI: 1.13-3.38). Univariate analysis showed that patients in each treatment group, had comparable 2-year OS rates regarding patient's age, gender, pathologic subtype, and histologic grade (p>0.05). Disease stage in each group and tumor site in CRT group significantly affected OS rates (p<0.05). Conclusions:Survival rates were statistically significant higher in patients treated with CRT than in those underwent esophagectomy. Prognostic factors that affected survival were disease stage in each treatment group and tumor site in CRT group.

show abstract

“…Chiu et al (Chiu et al, 2005) conducted a prospective randomized trial that compared the efficacy and survival outcome of chemoradiation with that of esophagectomy as a curative treatment. In this multicenter trial, 80 patients with potentially resectable squamous cell carcinoma of the mid or lower thoracic esophagus were randomized to esophagectomy or chemoradiotherapy.…”

Section: Comparison Of Definitive Chemoradiation and Surgerymentioning

confidence: 99%

Nonsurgical Management of Esophageal Cancer

Safa¹,

Reda²

2012

Esophageal Cancer - Cell and Molecular Biology, Biomarkers, Nutrition and Treatment

View full text Add to dashboard Cite

Multicenter Prospective Randomized Trial Comparing Standard Esophagectomy With Chemoradiotherapy for Treatment of Squamous Esophageal Cancer: Early Results From the Chinese University Research Group for Esophageal Cancer (CURE)

Cited by 145 publications

References 39 publications

Cetuximab inhibits cisplatin-induced activation of EGFR signaling in esophageal squamous cell carcinoma

Cetuximab inhibits cisplatin-induced activation of EGFR signaling in esophageal squamous cell carcinoma

Chemoradiation Compared to Surgery Alone in Patients With Non- Metastatic Esophageal Carcinoma

Nonsurgical Management of Esophageal Cancer

Contact Info

Product

Resources

About